ESCHER-GROUP
9.10.2018 07:12:12 CEST | Business Wire | Press release
Post-Expo 2018, Booth #B1.360 – Escher Group , the company transforming the postal and courier market with their innovative customer engagement platform, today announced that Nick Manolis has been named chief executive officer (CEO) of Escher, and that he has also been appointed to the company’s board of directors. For more than two decades, postal operators and couriers have relied on Escher to improve their customer experience at all points of engagement, accelerate service delivery and help them to transform their business to a more efficient variable cost model in a budget-constrained world. Escher has emerged as the worldwide market leader in customer engagement solutions for postal point-of-service (POS), and Manolis will be responsible for leading the company’s continued global expansion.
“Nick is a proven executive in leading high-performing, customer-centric technology companies,” said Matthew Peacock, founding partner at Hanover and Escher board member. “That talent combined with his success in innovating global retail platform solutions makes him a perfect fit to lead Escher as the company looks to expand its reach globally into new countries, and postal and courier markets.”
Outdated IT infrastructure and antiquated operating models no longer work for postal operators and couriers who need to manage the growth of parcels and adapt to today’s digitally savvy customers who want to be engaged on their own terms. Forward-looking postal executives are investing in customer engagement platforms to provide the best customer experience, increase revenues and move to a variable cost model.
With its unique and purpose-built customer engagement platform, Escher enables postal operators to shift to modern and profitable customer engagement strategies that embrace today’s digitally disruptive world. With new and deeper points of engagement – including third-party locations, kiosks, expanded pick-up drop-off (PUDO) locations and mobile point of sale – Escher makes it easier for postal customers to do business. Escher drives efficiency by automating and streamlining business processes and easily operationalizing new points of engagement. New services can be rolled out in days and third-party services can be implemented overnight.
With 25 unique post-centric technology patents, Escher has been able to deploy more than 350 thousand customer engagement points globally, which has resulted in more than two billion transactions processed annually. Escher has transformed how 35 postal operators around the globe profitably interact with their customers.
“Postal operators and couriers worldwide rely on Escher as they make the shift to a modern and profitable customer engagement strategy and embrace today’s digitally disruptive world. Our platform allows them to rapidly deliver new services and capabilities, while also providing a superior customer experience. With Escher, postal executives can do more with the resources with which they are entrusted,” said Nick Manolis. “I am honored to work with the exceptional team at Escher and the posts we serve globally.”
Manolis has spent the last ten years at TrueCommerce, a global provider of retail trading partner connectivity and integration solutions, as president and CEO. Under Manolis’ leadership, TrueCommerce provided a global trading platform that connected 12,000 suppliers with nearly 92,000 retailers worldwide.
Meet Manolis and the Escher team, and learn more about Escher’s customer engagement platform at Post-Expo booth #B1.360.
About Escher
Escher is transforming postal operators and couriers worldwide, enabling them to engage today’s digitally savvy customers across all points of engagement. With Escher’s unique, purpose-built customer engagement platform, posts can drive superior customer experience, with greater speed and better economics. Learn more: www.eschergroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181008005847/en/
Contact:
Media Contact 280blue, Inc. Amanda McKinney amanda@280blue.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom